Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma

NCT02098291 is registered in ClinicalTrials.gov with Cancer Advances Inc. as lead sponsor.

NCT NCT02098291
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02098291 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II, Open, Single-center Study to Determine the Antibody Response to Gastrimmune and Its Safety and Tolerability in Patients With Advanced Pancreatic Carcinoma
Lead sponsor
Cancer Advances Inc.
Phase
Phase 2
Overall status
Completed
Start date
April 30, 1999
Completion date
February 28, 2002
Enrollment
34 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer